• Image of Rimactane medication

    • RIFAMPIN (Generic for RIFADIN)

    • QTY 60
    • 300 MG
    • Capsule

RIFAMPIN (RIF am pin) treats infections caused by bacteria. It belongs to a group of medications called antibiotics. It will not treat colds, the flu, or infections caused by viruses.

RIFAMPIN (Generic for RIFADIN) Lifestyle Interactions

  • Rifampin 300mg, Oral capsule

    • Interaction: Alcohol
    • Severity: Major
    • Notes for Consumers: Drinking alcohol beverages while taking Rifampin can increase your risk of developing liver problems. It is best to avoid alcohol-containing beverages while taking Rifampin. Your health care provider will need to do blood tests to check your liver before and during your treatment with Rifampin. Discuss any new or worsening side effects, such as stomach pain, nausea, vomiting, dark colored urine, or yellowing of eyes or skin, with your health care provider.
    • Notes for Professionals: Rifampin is associated with dose-related hepatoxicity. Daily use of ethanol while receiving rifampin increases the risk of drug-induced hepatitis. Liver-function tests should be conducted prior to and every 2-4 weeks during treatment in patients who consume ethanol routinely while receiving rifampin therapy.

  • Rifampin 300mg, Oral capsule

    • Interaction: Marijuana
    • Severity: Moderate
    • Notes for Consumers: The effects of marijuana may be decreased if combined with this medicine. Do not drive or operate machinery until you know how this combination will affect you. Contact your health care provider right away if you notice slurred speech, confusion, severe drowsiness, increased heart rate, or any other new or unusual side effects.
    • Notes for Professionals: The incidence of marijuana associated adverse effects may change following coadministration with rifampin. Rifampin is an inducer of CYP2C9 and CYP3A4, two isoenzymes responsible for the metabolism of marijuana's most psychoactive compound, delta-9-tetrahydrocannabinol (Delta-9-THC). When given concurrently with rifampin, the amount of Delta-9-THC converted to the active metabolite 11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC) may be increased. These changes in Delta-9-THC and 11-OH-THC plasma concentrations may result in an altered marijuana adverse event profile.

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.